Posts tagged "tirzepatide"

Blood Sugar Regulation

GLP-1 agonism is the headline. The full picture is three distinct peptide classes acting on glucose metabolism through three different mechanisms — and the honest protocol leads with the one that has actually passed regulatory scrutiny.

The peptide approach to blood sugar regulation splits into three distinct classes — incretin receptor agonists (GLP-1, dual GLP-1/GIP), mitochondrial-derived peptides (MOTS-c), and Khavinson bioregulators (Pankragen). Each sits on a different shelf of the evidence stack, each has a different risk profile, and the most common protocol error is treating them as interchangeable.

blood sugarmetabolic healthGLP-1semaglutidetirzepatide+5

Fat LossOutcome

Appetite Suppression

GLP-1 agonists became a cultural phenomenon because they deliver dramatic short-term weight loss. The honest framing is chronic-disease pharmacology — effective while taken, compensation when withdrawn, best used alongside the nutritional foundation the drug amplifies.

Peptide-based appetite suppression splits across four classes — incretin agonists (semaglutide, tirzepatide, retatrutide), amylin analogs (cagrilintide), hypothalamic peptides (BRP), and growth-hormone fragments (AOD-9604). The multi-pathway arms race is producing larger weight losses, the weight-regain-on-discontinuation pattern is producing harder questions, and the nutritional foundation is producing the difference between therapeutic weight loss and iatrogenic frailty.

appetite suppression

Metabolic HealthOutcome

Insulin Sensitivity

Tirzepatide's insulin-sensitivity effect comes mostly from direct metabolic reprogramming, not weight loss. MOTS-c bypasses the insulin receptor entirely. The Khavinson bioregulators target β-cell regeneration via epigenetics. The three stories land at very different evidence grades — and the highest-impact decision in the whole class is sourcing.

Peptide therapy for insulin sensitivity now spans three distinct mechanistic classes: incretin agonists (GLP-1, tirzepatide, retatrutide) acting at the hormonal layer, mitochondrial-derived peptides (MOTS-c) acting at the cellular-energy layer via AMPK, and epigenetic bioregulators (Khavinson peptides, Pancragen) attempting to restore gene expression in β-cells. Weight loss explains only 13–21% of tirzepatide's HOMA-IR improvement — the rest is direct metabolic reprogramming. MOTS-c is an exercise mimetic in early trials. Bioregulators are a Russian-literature frontier awaiting Western replication. Sourcing is the biggest preventable harm in the whole class.

PeptidesPeptide

Tirzepatide

The first dual-action incretin that outpaces single-agonist therapy across weight, glucose, heart failure, and sleep apnoea, while forcing medicine to reckon with the musculoskeletal cost of rapid metabolic transformation.

Tirzepatide is an imbalanced dual GIP/GLP-1 receptor agonist achieving 15-22.5% body weight reduction, HbA1c cuts of up to 2.6%, FDA approval for sleep apnoea, and a 38% reduction in heart failure events. Its biased agonism at the GLP-1 receptor avoids receptor desensitisation, but rapid weight loss raises real concerns about bone density and lean mass.

tirzepatide

SupplementsCompanion

Tirzepatide Supplements

The biochemical cofactors your body needs to support Tirzepatide therapy.

Evidence-based supplement companion for Tirzepatide: the first dual-action incretin that outpaces single-agonist therapy across weight, glucose, heart failure, and sleep apnoea, while forcing medicine to reckon with the musculoskeletal cost of rapid metabolic transformation.

tirzepatide

tirzepatide

tirzepatide

Protocols

Blood Sugar Regulation

Appetite Suppression

Insulin Sensitivity

Tirzepatide

Tirzepatide Supplements

Protocols

Blood Sugar Regulation

Appetite Suppression

Insulin Sensitivity

Tirzepatide

Tirzepatide Supplements